Anavex Life Sciences (AVXL) Cash from Operations (2010 - 2025)
Anavex Life Sciences (AVXL) posted Cash from Operations of 7151000.0 for Q4 2025, up 16.89% sequentially from 8604000.0 in Q3 2025, and up 41.0% YoY from 5071690.56 in Q4 2024.
Anavex Life Sciences (AVXL) Cash from Operations (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Cash from Operations for 16 years, with the latest figure at 7151000.0 in Q4 2025.
- Quarterly Cash from Operations rose 41.0% year-over-year to 7151000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 34075000.0 (up 4.32% YoY) and the FY2025 annual result came in at 39044000.0, down 26.72% from the prior year.
- Cash from Operations improved to 7151000.0 in Q4 2025 per AVXL's latest filing, from 8604000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 3500955.0 in Q4 2021 and troughed at 12464000.0 in Q2 2025.
- A 5-year average of 7577131.1 and a median of 7317422.5 in 2021 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2021 and 2025: Cash from Operations jumped 55.52% in 2021, then tumbled 140.62% in 2025.
- Over 5 years, Cash from Operations stood at 3500955.0 in 2021, then sank by 65.5% to 5794000.0 in 2022, then slipped by 26.3% to 7318000.0 in 2023, then tumbled by 65.62% to 12120000.0 in 2024, then jumped by 41.0% to 7151000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 7151000.0, 8604000.0, and 12464000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | -7.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.15 Mn |
| Dec 31, 2025 | -7.15 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Sep 30, 2023 | -5.85 Mn |
| Sep 30, 2023 | -5.85 Mn |